REG - Uniphar PLC - Notice of AGM & Annual Report & Dividend Update

UnipharAnnouncement

06/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230406:nRSF5254Va&default-theme=true

RNS Number : 5254V  Uniphar PLC  06 April 2023

 

Publication of Notice of Annual General Meeting and Annual Report and Dividend
Update

 

 

Dublin, London | 6 April 2023: Uniphar plc (the "Company" or "Uniphar") wishes
to announce that it is today posting to shareholders its Notice of Annual
General Meeting ("AGM") for 2023 together with its annual report and accounts
for the year ended 31 December 2022 ("Annual Report"). The AGM will be held at
11.00 a.m. on 11 May 2023 at the offices of William Fry LLP, 2 Grand Canal
Square, Dublin 2, D02 A342.

Uniphar values the participation of its shareholders at its AGM and encourages
all shareholders to take part in the meeting either in person or by voting and
raising questions in advance.

The Notice of Meeting, Form of Proxy, Annual Report and accounts are available
to view on the Company's website at
https://www.uniphar.ie/static/investors/shareholder-centre/agm/agm-2023/
(https://www.uniphar.ie/static/investors/shareholder-centre/agm/agm-2023/)
and will be available for inspection during normal business hours on any
business day from today until the conclusion of the AGM at the registered
office of the Company.

Proxy voting can be carried out in advance of the AGM. Details of how to do so
are set out in further detail in the Notice of Meeting.

A conference call facility will be provided to allow shareholders to listen
live to the business of the AGM. Please note that you will not be able to use
this facility to vote, raise points or issues or ask questions. If you wish to
listen live to the AGM proceedings, you can register for the conference call
and receive participant log-in detailsat
https://www.uniphar.ie/static/investors/shareholder-centre/agm/agm-2023/
(https://www.uniphar.ie/static/investors/shareholder-centre/agm/agm-2023/) .
Shareholders availing of this facility should ensure to submit any votes in
advance of the meeting as it will not be possible to vote using the conference
call facility.

Shareholders are invited to submit questions in writing in advance of the
meeting either by email to companysecretary@uniphar.ie
(mailto:companysecretary@uniphar.ie) or by post to the Company Secretary,
Uniphar plc, 4045 Kingswood Road, Citywest Business Park, Co. Dublin, D24
V06K, Ireland. Questions must be received by 11.00 a.m. on 9 May 2023.
Shareholders must include their Shareholder Reference Number (as set out on
their Form of Proxy) with any question submitted.

Dividend Update

This announcement also amends the final dividend amount per share for approval
at the AGM to €0.0113 per ordinary share, from €0.011 per ordinary share
as published in the 2022 preliminary results released on 28 February 2023.

 

 

For further details contact:

 Uniphar Group                                            Tel: +353 (0) 1 428 7777

 Allan Smylie, Head of Strategy and IR

 Davy (Joint Corporate Broker, Nominated Advisor and      Tel: +353 (0) 1 679 6363

 Euronext Growth Listing Sponsor)

 Barry Murphy

 Niall Gilchrist

 RBC Capital Markets (Joint Corporate Broker)             Tel: +44 (0) 20 7653 4000

 Jonathan Hardy

 Jamil Miah

 Stifel Nicolaus Europe Limited (Joint Corporate Broker)  Tel: +44 (0) 20 7710 7600

 Matt Blawat

 Ben Maddison

 Francis North

 Q4 PR                                                    Tel: +353 (0) 1 475 1444

 Iarla Mongey, Public Relations Advisor to Uniphar Group

 

 

About Uniphar plc

 

Headquartered in Dublin, Ireland, the Uniphar Group is an international
diversified healthcare services business servicing the requirements of more
than 200 multinational pharmaceutical and medical technology manufacturers
across three divisions - Commercial & Clinical, Product Access and Supply
Chain & Retail. The Group is active in Europe, North America, APAC and
MENA.

 

The Company's vision is to improve patient access to pharmaco-medical products
and treatments by enhancing connectivity between manufacturers and healthcare
stakeholders. Uniphar represents a strong combination of scale, growth, and
profitability.

 

Commercial & Clinical

In Commercial & Clinical, the Group provides outsourced sales, marketing
& distribution solutions to multinational pharmaceutical and medical
device manufacturers. Active in Ireland, the UK, Benelux, the Nordics, Germany
and the US, the Group is growing with its clients to provide pan-European
solutions, with a targeted service offering in the US. Uniphar has built fully
integrated digitally enabled customer centric solutions that are supported by
our highly experienced and clinically trained teams, leveraging our digital
technology and insights which allows us to deliver consistently exceptional
outcomes for our clients.

 

Product Access

In Product Access, the Group is growing two distinct service offerings: 1) "On
Demand", which are pharmacy led solutions for sourcing and supplying
unlicensed medicines to meet the needs of both retail and hospital
pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions
for controlling the release of speciality medicines for specifically approved
patient populations in agreed markets. The Group currently delivers product
access solutions on a global basis.

 

Supply Chain & Retail

Uniphar is an established market leader in Ireland with c. 53% market share in
the wholesale/hospital market, supported by a network of 423 owned, franchised
and symbol group pharmacies. The business supports the diverse customer base
through the provision of strong service levels coupled with innovative
commercial initiatives. Supply Chain & Retail is an Irish only business
for the Group, although the manufacturer relationships and infrastructure are
also utilised for the benefit of the Commercial & Clinical and Product
Access divisions.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAUPUGUCUPWGCA